Kinetics of selected serum markers of fibrosis in patients with dilated cardiomyopathy and different grades of diastolic dysfunction of the left ventricle.
diastolic dysfunction
dilated cardiomyopathy
markers of fibrosis
Journal
Cardiology journal
ISSN: 1898-018X
Titre abrégé: Cardiol J
Pays: Poland
ID NLM: 101392712
Informations de publication
Date de publication:
2020
2020
Historique:
received:
13
07
2018
accepted:
08
11
2018
revised:
09
10
2018
pubmed:
30
11
2018
medline:
18
9
2021
entrez:
29
11
2018
Statut:
ppublish
Résumé
Fibrosis of the extracellular matrix (ECM) in dilated cardiomyopathy (DCM) is common and compromises both systolic and diastolic function. The aim of this study was to investigate the kinetics of ECM fibrosis markers over a 12 month follow-up in patients with DCM based on the severity of diastolic dysfunction (DD). Seventy consecutive DCM patients (48 ± 12.1 years, ejection fraction 24.4 ± 7.4%) were included in the study. The grade of DD was determined using the ASE/EACVI algorithm. Markers of ECM fibrosis were measured at baseline and at 3 and 12 month follow-ups: collagen type I and III (PICP, PINP, PIIICP, PIIINP), transforming growth factor beta-1 (TGF1-b), connective tissue growth factor (CTGF) and galectin-3 were measured. Patients were divided into three groups according to DD severity: 30 patients with grade I, 18 with grade II and 22 with grade III of DD. Levels of PICP, PINP were increased over a 12-month period, while PIIINP decreased and PIIICP unchanged. Levels of TGF1-b decreased from the 3 to the 12-month points in grade I and II DD, and in grade III they remained unchanged. Levels of CTGF decreased over 12 months in grade III DD but were unchanged in grades I and II. Galectin-3 levels remained the same over all observation periods, irrespective of DD grade. Regardless of the DD grade, markers of collagen type I synthesis increased, markers of collagen type III decreased. Levels of TGF and CTGF had a tendency to decrease. Galectin-3 was revealed not to be a marker discriminating the severity of DD.
Sections du résumé
BACKGROUND
Fibrosis of the extracellular matrix (ECM) in dilated cardiomyopathy (DCM) is common and compromises both systolic and diastolic function. The aim of this study was to investigate the kinetics of ECM fibrosis markers over a 12 month follow-up in patients with DCM based on the severity of diastolic dysfunction (DD).
METHODS
Seventy consecutive DCM patients (48 ± 12.1 years, ejection fraction 24.4 ± 7.4%) were included in the study. The grade of DD was determined using the ASE/EACVI algorithm. Markers of ECM fibrosis were measured at baseline and at 3 and 12 month follow-ups: collagen type I and III (PICP, PINP, PIIICP, PIIINP), transforming growth factor beta-1 (TGF1-b), connective tissue growth factor (CTGF) and galectin-3 were measured.
RESULTS
Patients were divided into three groups according to DD severity: 30 patients with grade I, 18 with grade II and 22 with grade III of DD. Levels of PICP, PINP were increased over a 12-month period, while PIIINP decreased and PIIICP unchanged. Levels of TGF1-b decreased from the 3 to the 12-month points in grade I and II DD, and in grade III they remained unchanged. Levels of CTGF decreased over 12 months in grade III DD but were unchanged in grades I and II. Galectin-3 levels remained the same over all observation periods, irrespective of DD grade.
CONCLUSIONS
Regardless of the DD grade, markers of collagen type I synthesis increased, markers of collagen type III decreased. Levels of TGF and CTGF had a tendency to decrease. Galectin-3 was revealed not to be a marker discriminating the severity of DD.
Identifiants
pubmed: 30484268
pii: VM/OJS/J/59268
doi: 10.5603/CJ.a2018.0143
pmc: PMC8079113
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
726-734Références
BMC Res Notes. 2012 Nov 14;5:636
pubmed: 23151377
Cardiol J. 2017;24(1):35-42
pubmed: 27748500
Eur J Heart Fail. 2014 Feb;16(2):163-72
pubmed: 24464932
J Am Soc Echocardiogr. 2016 Apr;29(4):277-314
pubmed: 27037982
Heart. 2004 Jun;90(6):650-4
pubmed: 15145870
Curr Heart Fail Rep. 2010 Mar;7(1):1-8
pubmed: 20425490
Herz. 2015 Aug;40(5):788-94
pubmed: 25990624
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
Am J Med Sci. 2006 Mar;331(3):131-3
pubmed: 16538073
Cardiovasc Pathol. 2007 Mar-Apr;16(2):69-74
pubmed: 17317538
Am J Cardiol. 1995 May 1;75(14):913-8
pubmed: 7733000
Sci Rep. 2015 Nov 19;5:17007
pubmed: 26582585
Cardiol J. 2018;25(6):722-731
pubmed: 28840590
Int J Cardiol. 2007 Nov 30;122(3):e36-8
pubmed: 17920710
Inflamm Res. 2016 Dec;65(12):941-949
pubmed: 27516211
Mol Cell Biol. 2015 Jun;35(12):2154-64
pubmed: 25870108
Circulation. 2003 Feb 25;107(7):984-91
pubmed: 12600911
Circulation. 2005 Nov 8;112(19):2940-5
pubmed: 16275882
Cytokine. 2012 Nov;60(2):341-5
pubmed: 22878343
Circulation. 1999 Jun 1;99(21):2750-6
pubmed: 10351968
Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70
pubmed: 25712077
Cytokine. 2017 Aug;96:217-227
pubmed: 28460256
Hypertension. 2002 Feb;39(2):258-63
pubmed: 11847194
Circ Heart Fail. 2017 Mar;10(3):
pubmed: 28288987
Congest Heart Fail. 2008 Nov-Dec;14(6):302-6
pubmed: 19076852
Circulation. 2000 Oct 10;102(15):1788-94
pubmed: 11023933
Circulation. 2004 Sep 7;110(10):1263-8
pubmed: 15313958
J Mol Cell Cardiol. 2011 Oct;51(4):600-6
pubmed: 21059352
J Am Coll Cardiol. 1995 May;25(6):1263-72
pubmed: 7722119